Skip Navigation

European Heart Journal 1995 16(Supplement A):6-10; doi:10.1093/eurheartj/16.suppl_A.6
Copyright © 1995 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nieuwenhuizen, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nieuwenhuizen, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 The European Society of Cardiology

Biochemistry and Measurement of Fibrinogen

W. Nieuwenhuizen

Gaubius Laboratory TNO-PG, Leiden The Netherlands

Correspondenc: W. Nieuwenhuizen, Gaubius Laboratory TNO-PG, P.O. Box 2215, 2301 CE Leiden, The Netherlands.

Fibrinogen is a large heterogeneous family of closely related molecules consisting of three pairs of non-identical polypeptide chains: two A{alpha}-, two Bβ- and two {gamma}-chains, held together by disulphide bridges. The heterogeneity of fibrinogen is due to heterogeneities in all three chains. Four main types of assay are used to determine fibrinogen: clotting rate (Clauss), clottable protein, precipitation and immunological assays. Heterogeneities may differ from person to person and may affect the apparent fibrinogen concentrations in different assays. A further complicating factor was, until recently, the lack of an international fibrinogen standard. The ratio of Clauss: enzyme immunoassay (EIA) for high+low molecular weight fibrinogen decreases during therapy for acute myocardial infarction and increases again after thrombolytic therapy to above normal values. Furthermore, high molecular weight fibrinogen tends to clot more easily than low molecular weight fibrinogen. This suggests that high molecular weight fibrinogen might be associated with increased thrombotic risk. Fibrinogen assessed by a functional assay (Clauss) alone is strongly associated with ischaemic heart disease. Although not proven, it is conceivable that a fibrinogen with a Clauss: EIA ratio of >1 has an even stronger association in epidemiological studies.

Key Words: Fibrinogen • molecular heterogeneity • polymerization • measurement • functionality of fibrinogen


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
D. E. Gutstein and V. Fuster
Pathophysiology and clinical significance of atherosclerotic plaque rupture
Cardiovasc Res, February 1, 1999; 41(2): 323 - 333.
[Abstract] [Full Text] [PDF]

Home page
 Vasc MedHome page
V. Fuster, J. J. Badimon, and J. H Chesebro
Atherothrombosis: mechanisms and clinical therapeutic approaches
Vascular Medicine, August 1, 1998; 3(3): 231 - 239.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.